Irritable bowel syndrome: low dose antidepressant improves symptoms
BMJ · 2024
DOI: 10.1136/bmj.q871 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, 2024. Verfasst von Helen Saul und 3 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Evidence, Twickenham, UK. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Amitriptyline. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
The study Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:1773-85. To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/irritable-bowel-syndrome-low-dose-antidepressant-improves-symptoms/
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NIHR Evidence, Twickenham, UK.
- University of Leeds.
Zitieren
APA
Saul, H., Cassidy, S., Swaithes, L., & Ford, A. C. (2024). Irritable bowel syndrome: low dose antidepressant improves symptoms. BMJ. https://doi.org/10.1136/bmj.q871
Vancouver
Saul H, Cassidy S, Swaithes L, Ford AC. Irritable bowel syndrome: low dose antidepressant improves symptoms. BMJ. 2024. doi:10.1136/bmj.q871
BibTeX
@article{Saul2024,
author = {Saul, Helen and Cassidy, Samantha and Swaithes, Laura and Ford, Alexander C},
title = {Irritable bowel syndrome: low dose antidepressant improves symptoms},
journal = {BMJ},
year = {2024},
doi = {10.1136/bmj.q871}
}
EUVIMED